Stifel Nicolaus Issues Pessimistic Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price objective decreased by Stifel Nicolaus from $273.00 to $261.00 in a research note published on Friday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the medical research company’s stock.

A number of other equities analysts have also commented on the stock. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Redburn Atlantic initiated coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Deutsche Bank Aktiengesellschaft cut their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Trading Down 0.9 %

Shares of NYSE IQV opened at $208.13 on Friday. The business’s 50 day moving average price is $200.53 and its 200-day moving average price is $219.80. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The company has a market cap of $37.78 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts expect that IQVIA will post 10.81 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IQV. Sequoia Financial Advisors LLC raised its position in IQVIA by 13.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 85,299 shares of the medical research company’s stock worth $16,762,000 after buying an additional 10,245 shares during the last quarter. PFG Advisors raised its holdings in shares of IQVIA by 45.3% during the fourth quarter. PFG Advisors now owns 6,068 shares of the medical research company’s stock worth $1,192,000 after purchasing an additional 1,893 shares during the last quarter. Inspire Advisors LLC boosted its holdings in IQVIA by 10.1% in the fourth quarter. Inspire Advisors LLC now owns 2,584 shares of the medical research company’s stock valued at $508,000 after purchasing an additional 236 shares during the last quarter. Citizens Financial Group Inc. RI grew its position in IQVIA by 14.5% during the 4th quarter. Citizens Financial Group Inc. RI now owns 2,820 shares of the medical research company’s stock worth $554,000 after purchasing an additional 357 shares during the period. Finally, Independent Advisor Alliance raised its stake in shares of IQVIA by 49.7% during the 4th quarter. Independent Advisor Alliance now owns 1,729 shares of the medical research company’s stock valued at $340,000 after buying an additional 574 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.